Saving and improving lives by making it easier to develop medical devices with electronics and software is the mission of the newly launched NSW Active MedTech Community.
The Australian Government is looking to maximise the economic potential of the medicinal cannabis industry.
US scientists have developed a contraceptive patch with a novel effervescent backing that separates from an array of microneedles after one minute.
USC biomedical engineers have proposed a new ultrasonic method to enable acoustic control and real-time tracking of cancer drugs within the body.
The work serves as a significant step towards creating grafts that are more like the skin our bodies produce naturally.
According to Fredrik Sundberg, PhD, global director of strategic customer relations at GE Healthcare, the key to successfully launching a drug product on the market is to thoroughly understand the drug development process.
A new drug blocks one of cancer's key evolutionary escape routes from chemotherapy, reinvigorating the response to chemotherapy in cancers that have become resistant.
PYC Therapeutics has entered into a commercial collaboration with Lions Eye Institute to develop drugs for a leading cause of blinding eye disease.
Metal–organic frameworks (MOFs) could present a viable platform for delivering a potent anticancer agent to cells.
Biomedical engineers brought together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.
Scientists have developed a compound of the metal iridium that will kill cancer cells in culture even when oxygen concentration is low.
The vaccine candidate has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Researchers have discovered that the inflammatory molecule IL23, investigated for a number of autoimmune diseases, is critical to osteosarcoma formation and progression.
A simple arthritis drug could be an effective, low-cost solution to treat patients with blood cancers such as polycythemia vera (PV) and essential thrombocythemia (ET).
The iQ Group Global has announced its acquisition of a novel anticancer drug platform, known as TEX Core, from the University of Texas.